Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Valereum, Helium One, Helix Exploration, Atlantic Lithium, Ariana Resources, Solvonis Therapeutics

Valereum, Helium One, Helix Exploration, Atlantic Lithium, Ariana Resources, Solvonis Therapeutics

Valereum PLC (AQSE:VLRM) expects around $600,000 from listing a new Wageen digital token on VLRM Markets. The WAG1 token targets an 11% annual return, with exposure to Latin American mobility services. Read more

Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) has commissioned its Galactica helium plant in Colorado and produced first gas. First helium sales are expected in January, with drilling planned to lift output through 2026. Read more

HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) is closing in on first helium production at its Rudyard project in Montana. Final equipment is arriving this week, while drilling pauses briefly due to winter weather. Read more

Atlantic Lithium Ltd (AIM:ALL, ASX:A11, OTCID:ALLIF) says it’s confident its Ewoyaa mining lease will be approved in Ghana. Revised fiscal terms are now before parliament, with a committee review expected in the new year. Read more

Ariana Resources PLC (AIM:AAU, ASX:AA2) has struck a binding deal with Hongkong Xinhai Mining Services that will inject an initial A$8 million of fresh cash into the company. The deal funds feasibility work at its Dokwe gold project in Zimbabwe and brings a new strategic shareholder onto the register. Read more

Solvonis Therapeutics PLC (LSE:SVNS) says 2025 reshaped the business, setting up a catalyst-heavy year ahead. Its lead alcohol addiction drug is in phase three trials, with multiple other programmes advancing into 2026. Read more

Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK